Senate passes FDARA overwhelmingly, ahead of September deadline.
Christine Blank, Contributing Editor
Generic drugs make up 90% of prescriptions.
Savings from generic and biosimilar drugs are making PBMs and pharmacies, as well as patients, happy.
Pharmacy chains are forcing lower generic prices for their customers.
FDA will shorten the review periods for priority generic drugs by two months.
Two recent generic cholesterol-lowering drugs are helping reduce health-care costs.
Patients are less like to buy a requested brand name prescription than a generic one.
High court ruling should make biosimilars available faster.
Good glucose control can help children and teens with type 1 diabetes boost their quality of life.
Interventions by pharmacists can help improve the results of diabetes clinical trials.